The main finding of this study was that IL-1 inhibition with anakinra, but not IL-6 inhibition with, significantly reduced mortality in the overall population of in-hospital patients with COVID-19, respiratory insufficiency, and hyperinflammation. Here, IL1B is linked to COVID-19.